Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 236Carcinoma, Non-Small-Cell Lung 78Carcinoma, Renal Cell 61Neoplasm Metastasis 52Neoplasms 47Prostatic Neoplasms 34Uveal Melanoma 29Lung Neoplasms 28Pancreatic Neoplasms 27Carcinoma, Hepatocellular 25Brain Neoplasms 23Sarcoma 22Colorectal Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Skin Neoplasms 17Kidney Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Mesothelioma 13Uterine Cervical Neoplasms 12Recurrence 12Glioblastoma 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

Gemcitabine 4Cisplatin 4pembrolizumab 3Carboplatin 3erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1niraparib 1enfortumab vedotin 1cabozantinib 1atezolizumab 1Tiragolumab 1Sunitinib 1Radiotherapy 1Radiation Dose Hypofractionation 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Everolimus 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urothelial Cancer × Ipilimumab × Clear all
NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡